Debevoise Advises The Carlyle Group in Its Investment in TriNetX

21 September 2020

Debevoise & Plimpton LLP is advising The Carlyle Group (NASDAQ: CG) in its investment in TriNetX, a leading global health research network optimizing clinical research to bring new therapies to market faster. For more information, please see the company’s press release.

The Carlyle Group, which manages $221 billion of assets, is a global investment firm with deep industry expertise that deploys private capital across four business segments: corporate private equity, real assets, global credit and investment solutions. TriNetX is a global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient.

The Debevoise team is led by M&A partners Jennifer Chu and Kevin Rinker and includes M&A counsel David Iozzi and associates Lauren Beasley, Victoria Jimenez, Ethan McMahon, Bradley Polivka and Sergio Torres, benefits partner Jon Lewis and associate Zain Kazmi, tax partner Peter Furci and associate Jay Evans and intellectual property partner Jeffrey Cunard and associate Melody Godbolt.